Top Losers

  XOMA Corp (NASDAQ: XOMA) shares fell 18.3 percent to $5.10 after the company disclosed a significant step toward initiating pediatric Phase 2 clinical study for XOMA 358 in children with congenital hyperinsulinism. Puma Biotechnology Inc (NYSE: PBYI) dropped 15.4 percent to $44.55...

  ImmuCell Corporation (NASDAQ: ICCC) shares tumbled 15.2 percent to $6.63. ImmuCell reported the raising of $3.5 million through private placement. ImmuCell expects Q3 sales of $1.97 million and net operating earnings of $(25,000) to $75,000. RLJ Entertainment Inc (NASDAQ: RLJE)...

  PTC Therapeutics, Inc. (NASDAQ: PTCT) shares dropped 32 percent to $9.02 after the company reported a regulatory update on Translarna for nonsense mutation DMD. Skypeople Fruit Juice Inc (NASDAQ: SPU) shares dropped 18.9 percent to $6.21 after declining 3.04 percent on Friday....

  Ocean Power Technologies Inc (NASDAQ: OPTT) tumbled 24.9 percent to $3.02. Ocean Power priced 2.4 million shares at $2.75 per share. Taylor Devices, Inc. (NASDAQ: TAYD) shares fell 24.5 percent to $14.92. Taylor Devices reported Q1 earnings of $0.06 per share on revenue of $5.76...

  Fluidigm Corporation (NASDAQ: FLDM) shares dropped 26.2 percent to $5.20 after the company reported weak preliminary revenue for the third quarter. Flex Pharma Inc (NASDAQ: FLKS) declined 21 percent to $8.85 after the company disclosed that it has initiated a Phase 2 efficacy study...

  Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) shares dropped 19.1 percent to $5.67 after the company issued a profit warning for the third quarter. IEC Electronics Corp (NYSE: IEC) shares declined 18.4 percent to $4.16. IEC Electronics confirmed workforce reduction of 73 employees...

  Clovis Oncology Inc (NASDAQ: CLVS) shares declined 14 percent to $30.77 after the company disclosed its oral presentation of the primary efficacy and safety data for rucaparib from its NDA dataset at the 2016 ESMO Congress. The company indicated that the drug candidate is under FDA...

  Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares tumbled 47.1 percent to $37.17 after the company disclosed that it has decided to discontinue the Revusiran development. Leerink Swann downgrades Alnylam Pharmaceuticals from Outperform to Market Perform and lowered the price target...

  Great Basin Scientific Inc (NASDAQ: GBSN) shares dipped 35.5 percent to $0.477. Great Basin Scientific shares have dipped 99.99 percent over the past 52 weeks, while the S&P 500 index has gained 8.23 percent in the same period. Kelly Services, Inc. (NASDAQ: KELYB) shares fell...

  Trinity Biotech plc (ADR) (NASDAQ: TRIB) shares dipped 51 percent to $6.36 after the company disclosed that it has withdrawn its 510(k) premarket notification submission for its Meritas Troponin-I Test and Meritas Point-of-Care Analyzer. Iradimed Corp (NASDAQ: IRMD) shares tumbled...

  Great Basin Scientific Inc (NASDAQ: GBSN) shares tumbled 29.3 percent to $1.62. Great Basin Scientific shares have dropped 99.98 percent over the past 52 weeks, while the S&P 500 index has increased 9.12 percent in the same period. Real Goods Solar, Inc. (NASDAQ: RGSE) dropped...

  Vectrus Inc (NYSE: VEC) shares tumbled 46.3 percent to $14.85 on news of the government rejecting the company's contract proposal to provide comprehensive support services for all US Army facilities in Kuwait. Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) shares dropped 43.3...

  Intra-Cellular Therapies Inc (NASDAQ: ITCI) shares tumbled 63.2 percent to $15.60 after its lead product candidate, ITI-007, failed a late-stage study in schizophrenia. Apparently, the drug couldn't beat the placebo, nor could it equal the performance of the active control...

  Caesars Entertainment Corp (NASDAQ: CZR) shares declined 14.9 percent to $8.05. Caesars Entertainment and Caesars Entertainment Operating Co. announced key economic terms of proposed consensual restructuring plan for CEOC. Alliance One International, Inc. (NYSE: AOI) shares fell 14...

  Pain Therapeutics, Inc. (NASDAQ: PTIE) shares dipped 53.6 percent to $1.27 after the company reported that it has received a complete response letter from the FDA. The FDA determined that REMOXY cannot be approved. DURECT Corporation (NASDAQ: DRRX) shares dropped 32.7 percent to $1....